Donald Notman compensation by year
OCULAR THERAPEUTIX Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $415,000 | $431,600 | $446,706 | $464,574 | $497,105 | $560,175 |
| Bonus | $199,200 | $194,317 | $180,916 | $212,194 | $274,200 | $406,127 |
| Stock awards | $0 | $0 | $292,780 | $215,557 | $881,433 | $855,600 |
| Option awards | $675,100 | $2,527,912 | $614,985 | $448,167 | $413,725 | $1,846,179 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $750 | $3,250 | $3,250 | $3,002 | $2,878 | $2,878 |
| Total | $1,290,050 | $3,157,079 | $1,538,637 | $1,343,494 | $2,069,341 | $3,670,959 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: OCULAR THERAPEUTIX, INC DEF 14A filed April 30, 2026, accession 0001104659-26-053176, and prior-year filings. Open the filing on EDGAR.
How this page was built: the OCULAR THERAPEUTIX, INC filed document, accession 0001104659-26-053176. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 115,000 | $1,396,100 | — |
| RSU | 41,091 | $498,845 | — |
| RSU | 18,519 | $224,821 | — |
| RSU | 7,356 | $89,302 | — |
| Option | 272,426 | — | $7.44 |
| Option | 22,402 | — | $8.56 |
| Option | 100,210 | — | $5.18 |
| Option | 45,141 | — | $3.88 |
Per the Outstanding Equity Awards at Fiscal Year-End table in OCULAR THERAPEUTIX, INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed April 30, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-31 | Sale | — | 1,099 | $10.24 | 366,529 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments OCULAR THERAPEUTIX discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $560,175 | $4,687,728 | $23,128 | $5,271,030 |
| Change in control and involuntary termination | $840,263 | $4,687,728 | $34,692 | $5,982,813 |
Per the Potential Payments Upon Termination or Change in Control table in OCULAR THERAPEUTIX, INC's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
OCULAR THERAPEUTIX’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Pravin Dugel | Executive Chairman, President and Chief Executive Officer | $35,946,958 |
| Nadia Waheed | Chief Medical Officer | $4,378,925 |
| Donald Notman · this page | Chief Financial Officer and Chief Operating Officer | $3,670,959 |
| Sanjay Nayak | Chief Strategy Officer | $3,463,405 |
| Steve Meyers | Chief Commercial Officer | $2,550,269 |
Donald Notman's compensation dossier, OCULAR THERAPEUTIX
You have read Donald Notman's totals and holdings. The dossier adds each equity grant OCULAR THERAPEUTIX disclosed for Donald Notman and OCULAR THERAPEUTIX's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full OCULAR THERAPEUTIX compensation record
free company briefThis page is one person within OCULAR THERAPEUTIX's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the OCULAR THERAPEUTIX proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order OCULAR THERAPEUTIX's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are OCULAR THERAPEUTIX's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order OCUL
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.